Multiple System Atrophy Therapeutics Market to Reach USD 213.3 Mn by 2033, Registering 4.8% CAGR

LOS ANGELES - Nov. 2, 2025 - PRLog -- Acumen Research And Consulting in its new comprehensive market study reveals that the Multiple System Atrophy Therapeutics Market is on track for steady expansion, propelled by rising awareness, diagnostic advances and an expanding therapeutic pipeline. The report offers deep insight into market size, market share, market growth, market trends and detailed market analysis across product, mechanism of action, end‑user and regional segments.

Multiple System Atrophy Therapeutics Market Statistics

• Market Size in 2024: USD 141.2 million
• Forecasted Market Size by 2033: USD 213.3 million
• Compound Annual Growth Rate (CAGR, 2025–2033): 4.8%
• North America Market Value (2024): approx. USD 51.72 million
• Asia‑Pacific Region Projected CAGR: over 5.5% during 2025‑2033
• Leading Product Segment (2024): Anle‑138b with 57% share of the product market

Market Overview & Growth Drivers

Multiple System Atrophy Therapeutics Market encompasses treatments for Multiple System Atrophy (MSA) — a rare, progressive neurodegenerative disorder affecting movement, autonomic function, coordination and balance. Growth in this market is driven by several compelling factors: increasing prevalence of MSA due to ageing populations globally; heightened R&D investment in disease‑modifying therapies; and improved diagnostic tools such as advanced neuroimaging and biomarkers allowing earlier detection.

Download PDF Sample Report: https://www.acumenresearchandconsulting.com/request-sample/3776

Multiple System Atrophy Therapeutics Market Trends & Analysis

Significant trends shaping the Multiple System Atrophy Therapeutics Market include:

• A strong shift toward disease‑modifying treatments rather than purely symptomatic care: Research is increasingly focused on therapies targeting alpha‑synuclein, neuroprotection, inflammation suppression and neuronal repair.
• Dominance of the Anle‑138b product segment: With roughly 57% market share in 2024, Anle‑138b is leading candidate in multiple system atrophy therapeutics market.
• Regional expansion in Asia‑Pacific: The Asia‑Pacific region is anticipated to grow at over 5.5% CAGR during 2025‑2033, underscoring growing awareness, healthcare infrastructure improvements and rising neurodegenerative disease burden in countries such as China, India and Japan.

Multiple System Atrophy Therapeutics Market Regional & Competitive Landscape

In terms of regional market share and opportunities, North America leads due to advanced healthcare systems, strong neurology research infrastructure and high awareness of neurodegenerative conditions. Asia‑Pacific region is emerging as the fastest‑growing region in the Multiple System Atrophy Therapeutics Market, bolstered by rising diagnostic capabilities, supportive government initiatives and increasing healthcare expenditure.

Key companies:

• Prana Biotechnology Ltd
• AFFiRiS AG
• Neuropore Therapies Inc
• Sumitomo Dainippon Pharma Co., Ltd
• AstraZeneca Plc
• MitoDys Therapeutics Ltd
• Modag GmbH
• Biohaven Pharmaceuticals, Inc
• Theravance Biopharma, Inc
• ProMIS Neurosciences Inc
• Corestem Inc

Read Full Report: https://www.acumenresearchandconsulting.com/multiple-system-atrophy-therapeutics-market